电话:
+86 (0512) 65829739
传真:
+86 (010) 6788 5057
电子邮件:
orders@antibodies-online.cn

TRAF3IP2 抗体 (AA 1-528)

The 兔 多克隆 anti-TRAF3IP2 antibody (ABIN7869454) specifically detects TRAF3IP2 in WB, ELISA 和 FACS. The antibody is reactive with 人, 大鼠 和 小鼠 samples.
产品编号 ABIN7869454
发货至: 中国
Contact our Customer Service for availability and price in your country. Contact Info

Our Local Distributor

中国
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
4A Biotech Co.,Ltd.
Tel +86 (0512) 65829739 传真 +86 (010) 6788 5057

Quick Overview for TRAF3IP2 抗体 (AA 1-528) (ABIN7869454)

抗原

See all TRAF3IP2 抗体
TRAF3IP2 (TRAF3 Interacting Protein 2 (TRAF3IP2))

适用

  • 41
  • 19
  • 15
  • 6
  • 1
  • 1
  • 1
  • 1
人, 大鼠, 小鼠

宿主

  • 49
  • 6
  • 1

克隆类型

  • 51
  • 5
多克隆

标记

  • 27
  • 3
  • 3
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
This TRAF3IP2 antibody is un-conjugated

应用范围

  • 47
  • 18
  • 13
  • 13
  • 9
  • 8
  • 6
  • 4
  • 3
  • 1
  • 1
Western Blotting (WB), ELISA, Flow Cytometry (FACS)
  • 抗原表位

    • 15
    • 8
    • 4
    • 4
    • 3
    • 3
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    AA 1-528

    原理

    TRAF3IP2 Antibody / TRAF3-interacting protein 2

    纯化方法

    Immunogen affinity purified

    免疫原

    E.coli-derived human TRAF3IP2 recombinant protein (Position: M1-H528) was used as the immunogen for the TRAF3IP2 antibody.

    亚型

    IgG
  • 应用备注

    Optimal dilution of the TRAF3IP2 antibody should be determined by the researcher.

    限制

    仅限研究用
  • 状态

    Lyophilized

    溶解方式

    Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL

    缓冲液

    Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4.

    储存条件

    4 °C,-20 °C

    储存方法

    After reconstitution, the TRAF3IP2 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.
  • 抗原

    TRAF3IP2 (TRAF3 Interacting Protein 2 (TRAF3IP2))

    别名

    TRAF3IP2

    背景

    TRAF3IP2 antibody detects TRAF3-interacting protein 2, encoded by the TRAF3IP2 gene on chromosome 6q21. TRAF3IP2 antibody is widely used in immunology, signal transduction, and inflammatory disease research. TRAF3IP2, also known as Act1, is a cytoplasmic adaptor protein that integrates signals from interleukin receptors, Toll-like receptors, and TNF receptor family members. It is critical for NF-kappaB and MAPK activation downstream of IL-17 signaling.

    Structurally, TRAF3IP2 is a ~65 kDa protein containing an SEFIR domain, a helix-loop-helix domain, and TRAF-binding motifs. These domains enable interactions with IL-17 receptor subunits, TRAF proteins, and kinases. TRAF3IP2 acts as a signal transducer bridging receptor complexes to downstream effectors, particularly in inflammatory pathways.

    Functionally, TRAF3IP2 is indispensable for IL-17 signaling, mediating proinflammatory gene expression in epithelial and immune cells. It also participates in antiviral responses, B cell maturation, and adaptive immunity. Researchers use TRAF3IP2 antibody to study cytokine signaling, inflammation, and host defense.

    Clinically, mutations in TRAF3IP2 are associated with psoriasis, psoriatic arthritis, and other autoimmune diseases. Polymorphisms in TRAF3IP2 influence susceptibility to inflammatory disorders, and dysregulated expression has been linked to cancer progression. Because IL-17 signaling is a therapeutic target, TRAF3IP2 is under investigation as a biomarker and potential drug target. NSJ Bioreagents supplies TRAF3IP2 antibody for immunology, inflammation, and disease mechanism studies.

    Experimentally, TRAF3IP2 antibody is used in western blotting to detect the ~65 kDa protein, in immunofluorescence to study cytoplasmic distribution, and in co-immunoprecipitation to examine receptor complexes. It is valuable in dissecting IL-17-mediated signaling cascades.

    UniProt

    O43734

    途径

    Production of Molecular Mediator of Immune Response
You are here: